Since 202 1, how has Hengrui Pharma's innovative drugs performed?

Since 20021,the company's innovative drugs have entered an intensive harvest period, and seven innovative drugs such as tumor, blood and endocrine have been approved for listing. Among them, Daxili tablet is the first CDK4/6 inhibitor in China, Riverumide is the first AR inhibitor in China, and Hertripopal is a new generation of TPO oral drug. At present, all three products are included in medical insurance through medical insurance negotiations. It is expected that 2023 will be a year of rapid growth in volume, which will drive the high growth of Hengrui's innovative medicine sector. Since 2023, repagliptin (Rezetan? ), otconazole and adebesumab (ariely? Three innovative drugs were listed, and the total number of independent research and development innovative drugs approved by the company reached 13, and two innovative drugs were introduced in cooperation; In addition, more than 80 independent innovative products are under clinical research and development, and more than 260 clinical trials are being carried out at home and abroad, forming a virtuous circle of listing, clinical and development.